Hervycta 440 + Injection

Last updated on 12 Nov 2024 | 01:07 AM (IST)

Hervycta 440 + Injection is used in the treatment of breast and stomach cancer. It works by killing the cancer cells by inhibiting HER2 (human epidermal growth factor receptor protein).

Genuine

Authenticity Assured

Prescription

required

Cold stored

Stored between 2-8°C

₹61336

₹63233

3% off

1 Injection

General Information

Contains

Trastuzumab (440mg)

Marketer

Dr Reddy's Laboratories Ltd

Storage

Store in a refrigerator (2 - 8°C). Do not freeze.

Preservative

Benzyl Alcohol

The content is shown in English

Product introduction

Hervycta 440 + Injection is given as an injection by a qualified medical professional. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

The most common side effects of this medicine include nausea, headache, rash, insomnia, and infection. This medicine may reduce the number of blood cells (decrease red blood and white blood cells) in your blood, thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells along with heart, liver, and blood uric acid levels. You must have to inform your doctor if you experience breathlessness, cough, shivering, swelling of legs and arm.

Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.

Uses of Hervycta Injection

Benefits of Hervycta Injection

Breast cancer
Hervycta 440 + Injection is used to treat breast cancer when other medicines have failed to show significant improvement. It helps to stop cancer growth and further spread and relieves the symptoms of breast cancer such as breast lumps, bloody discharge from nipple or changes in the shape or texture of the breast. This medicine is given as an injection by a doctor or nurse. Follow your doctor’s instructions carefully to get the most benefit.

Stomach cancer
Stomach cancer also known as gastric cancer, may occur in the inner lining (called mucosa) of the stomach or in the walls of the stomach. These are of various kinds depending on the origin, affected area and severity of the cancer. Hervycta 440 + Injection helps to kill the cancer cells and also stops their further growth and spread. Follow your doctor’s instructions carefully to get the most benefit.

Side effects of Hervycta Injection

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Common side effects of Hervycta

Anemia (low number of red blood cells)
Chills
Common cold
Cough
Decreased blood cells (red cells, white cells, and platelets)
Diarrhea
Fatigue
Fever
Headache
Heart failure
Infection
Insomnia (difficulty in sleeping)
Mucosal inflammation
Nausea
Rash
Stomatitis (Inflammation of the mouth)
Taste change
Upper respiratory tract infection
Weight loss

How to use Hervycta Injection

Your doctor or nurse will give you this medicine. Kindly do not self administer.

How Hervycta Injection works

Hervycta 440 + Injection is a recombinant IgG1 monoclonal antibody. It works against the HER2 (human epidermal growth factor receptor protein) receptors which are responsible for the over-proliferation of cancer cells in breast cancer and stomach cancer cells. It destroys the cancer cells by inhibiting HER2. It also inhibits various cancer-causing downstream signaling pathways.

All substitutes for Hervycta 440 + Injection

For information purposes only. Consult a doctor before taking any medicine.

Quick tips

It is given as an injection into your vein or under the skin, usually over 1 hour.
Use effective contraception method to prevent pregnancy while taking this medicine and for 7 months after you stop the treatment.
Your doctor will monitor your heart regularly while taking this medicine. Inform your doctor if you notice symptoms such as breathlessness, cough, shivering, swelling of legs and arm.
Inform your doctor if you are pregnant, planning pregnancy or breastfeeding.

Safety advice

Alcohol

UNSAFE

Hervycta 440 + Injection may cause excessive drowsiness with alcohol.

Pregnancy

CONSULT YOUR DOCTOR

Hervycta 440 + Injection is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.

Breast feeding

CONSULT YOUR DOCTOR

Hervycta 440 + Injection is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.

Driving

CONSULT YOUR DOCTOR

It is not known whether Hervycta 440 + Injection alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.

Kidney

SAFE IF PRESCRIBED

Hervycta 440 + Injection is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Hervycta 440 + Injection may not be needed in these patients. Please consult your doctor.

Liver

CONSULT YOUR DOCTOR

There is limited information available on the use of Hervycta 440 + Injection in patients with liver disease. Please consult your doctor.

Frequently asked questions

What are the serious side effects of Hervycta 440 + Injection?

There are various side effects related to Hervycta 440 + Injection such as sore throat, fever, chills, excessive tiredness, pale skin, nosebleeds, and other unusual bruising or bleeding. One can also experience stomach pain, seizures, hallucinations, muscle cramps, and spasms. Along with that, nausea or vomiting, loss of appetite, fatigue, rapid heart beat, discoloration of urine; decreased amount of urine, difficulty in urinating, pain when urinating, and other signs of infection can also be observed with the use of Hervycta 440 + Injection. You should call your doctor immediately if you notice any such symptoms.

How long after Hervycta 440 + Injection therapy can I get pregnant?

Women of child-bearing age should use effective contraception during Hervycta 440 + Injection therapy and for 7 months after completing the treatment. You can plan your pregnancy after 7 months of treatment with Hervycta 440 + Injection.

How long should Hervycta 440 + Injection be taken?

Patients with early breast cancer should take Hervycta 440 + Injection for 1 year or until disease recurs, whichever occurs first. It is not advised to extend the treatment beyond 1 year in patients of early breast cancer.

Is fasting required before administering Hervycta 440 + Injection?

No, fasting is not required before administering Hervycta 440 + Injection. It should be given under the guidance of a doctor who is experienced in giving cancer chemotherapy and should be given only by a healthcare professional.

How is Hervycta 440 + Injection given, intravenously or intramuscularly?

There are 2 different formulations available for administration of Hervycta 440 + Injection, one is given as an infusion into a vein (intravenous infusion) and the other is given as an injection under the skin (subcutaneous injection). It is important to check the product labels to ensure that the correct formulation is being given as prescribed. Hervycta 440 + Injection intravenous formulation is not for subcutaneous use and should be given as an intravenous infusion only. Your doctor may consider switching your Hervycta 440 + Injection intravenous treatment to Hervycta 440 + Injection subcutaneous treatment (and vice versa) if considered appropriate for you.

Can Hervycta 440 + Injection be given to HER2 negative cancer patients?

No, Hervycta 440 + Injection cannot be given in patients with HER2 negative cancer cells. Hervycta 440 + Injection belongs to class of monoclonal antibody. It binds selectively to a protein called human epidermal growth factor receptor 2 (HER2). HER2 is found, in large amounts, on the surface of some cancer cells. When Hervycta 440 + Injection binds to HER2, it stops the growth and spread of the cancer cells. Therefore, it is only effective in HER2 positive patients (in which HER2 is present) and will not be beneficial for HER2 negative patients (in which HER2 is not present).

Why has my doctor advised for investigations of heart?

Hervycta 440 + Injection when used with anthracycline class of anti-cancer medicines (eg doxorubicin) may adversely affect your heart. Hence, your doctor needs to check the health of your heart initially before starting treatment and during treatment.

How frequently heart investigations are required?

Heart investigations should be performed at the starting of the treatment. It should be repeated every 3 months during treatment and every 6 months after the discontinuation of treatment until 24 months from the last administration of Hervycta 440 + Injection. Those patients who already have heart-related problems will require investigations every 12 weeks.

Fact Box

Chemical Class

Monoclonal antibody (mAb)

Habit Forming

Therapeutic Class

ANTI NEOPLASTICS

Action Class

HER2/neu (ErbB2) Inhibitor- Monoclonal antibody

Related lab tests

Breast Cancer (CA 15.3/ ER/ PR)

References

Chabner BA, Barnes J, Neal J, et al. Targeted Therapies: Tyrosine Kinase Inhibitors, Monoclonal Antibodies, and Cytokines. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. pp. 1737.
Lake DF, Briggs AD, Akporiaye ET. Immunopharmacology. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. p. 978.
Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 1390-91.
Trastuzumab. South San Francisco, California: Genentech, Inc.; 1998 [revised Oct. 2010]. [Accessed 27 Mar. 2019] (online) Available from:
Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006. Trastuzumab. [Updated 2019 Jun 30]. [Accessed 19 Feb. 2020] (online) Available from:

Patient concerns

If any symtom of brest cancer if have whats the cure

Dr. Sanjay Singh Rai

Medical Oncology and Hematology

First is confirmation of breast cancerChance of cure depends on stage of cancer

BREAST CANCER , PET REPORT SAYS INFECTION IN SKELETON.

Dr. Sanjay Singh Rai

Medical Oncology and Hematology

Metastatic breast cancer, send me previous treatment details

Want to know more

We provide you with authentic, trustworthy and relevant information

Have issue with the content

Disclaimer

Tata 1mg's sole intention is to ensure that its consumers get information that is expert-reviewed, accurate and trustworthy. However, the information contained herein should NOT be used as a substitute for the advice of a qualified physician. The information provided here is for informational purposes only. This may not cover everything about particular health conditions, lab tests, medicines, all possible side effects, drug interactions, warnings, alerts, etc. Please consult your doctor and discuss all your queries related to any disease or medicine. We intend to support, not replace, the doctor-patient relationship.

Marketer details

Name: Dr Reddy's Laboratories Ltd
Address: Dr. Reddy's Laboratories Ltd., Village Malpur, P.O.Bhud, Baddi, Dist. Solan, H.P.

Vendor Details

Country of origin: India
A licensed vendor partner from your nearest location will deliver Hervycta 440 + Injection. Once the pharmacy accepts your order, the details of the pharmacy will be shared with you. Acceptance of your order is based on the validity of your doctor's ℞ and the availability of this medicine.

In case of any issues, contact us

Email ID: [email protected]
Phone Number: 0124-4166666
Address: 5th Floor Tower - B of the Presidency Building, 46/4 Mehrauli Gurgaon Road, Sector 14, Gurugram, Haryana-122001, India

Lab tests offered by us

Why we need a prescription?

Provide right medicines

Prescriptions are complex documents. We proof read and recheck at various steps to provide you the right medication in the correct form and dose

In accordance with the law

Most medicines cannot be sold without a valid prescription, as per the Drugs and Cosmetics Act, 1940 and Rules, 1945

Hervycta 440 + Injection

General Information

Contains

Marketer

Storage

Preservative

Product introduction

Uses of Hervycta Injection

Benefits of Hervycta Injection

Side effects of Hervycta Injection

How to use Hervycta Injection

How Hervycta Injection works

All substitutes for Hervycta 440 + Injection

Canmab 440mg Injection

Hertraz 440mg Injection

Herclon Injection

Haltrust 440 Injection

Vicentra 440mg Injection

Quick tips

Safety advice

Alcohol

Pregnancy

Breast feeding

Driving

Kidney

Liver

Frequently asked questions

What are the serious side effects of Hervycta 440 + Injection?

How long after Hervycta 440 + Injection therapy can I get pregnant?

How long should Hervycta 440 + Injection be taken?

Is fasting required before administering Hervycta 440 + Injection?

How is Hervycta 440 + Injection given, intravenously or intramuscularly?

Can Hervycta 440 + Injection be given to HER2 negative cancer patients?

Why has my doctor advised for investigations of heart?

How frequently heart investigations are required?

Fact Box

Chemical Class

Habit Forming

Therapeutic Class

Action Class

Related lab tests

Breast Cancer (CA 15.3/ ER/ PR)

References

Patient concerns

If any symtom of brest cancer if have whats the cure

BREAST CANCER , PET REPORT SAYS INFECTION IN SKELETON.

Want to know more

Have issue with the content

Disclaimer

Marketer details

Vendor Details

In case of any issues, contact us

Lab tests offered by us

Related/Popular tests